Sarepta Therapeutics Company Profile (NASDAQ:SRPT)

About Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics logoSarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD). It is focused on the development of its disease-modifying DMD drug candidates. It has received accelerated approval for its product, EXONDYS 51, indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. EXONDYS 51 is studied in clinical trials under the name of eteplirsen. Its next generation phosphorodiamidate morpholino oligomer (PMO)-based compounds are synthetic compounds that bind to complementary sequences of RNA by standard Watson-Crick nucleobase pairing. Its PMO-based chemistries are peptide conjugated PMO (PPMO), PMO-X and PMOplus.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $2.94449 billion
  • Outstanding Shares: 64,332,000
Average Prices:
  • 50 Day Moving Avg: $40.10
  • 200 Day Moving Avg: $34.92
  • 52 Week Range: $26.26 - $63.73
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -26.25
  • P/E Growth: 190.35
Sales & Book Value:
  • Annual Revenue: $56.77 million
  • Price / Sales: 52.95
  • Book Value: $6.83 per share
  • Price / Book: 6.84
  • EBIDTA: ($229,470,000.00)
  • Return on Equity: -63.65%
  • Return on Assets: -52.75%
  • Current Ratio: 5.92%
  • Quick Ratio: 5.29%
  • Average Volume: 2.62 million shs.
  • Beta: 1.04
  • Short Ratio: 3.09

Frequently Asked Questions for Sarepta Therapeutics (NASDAQ:SRPT)

What is Sarepta Therapeutics' stock symbol?

Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT."

How were Sarepta Therapeutics' earnings last quarter?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) issued its quarterly earnings data on Wednesday, July, 19th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.92) by $0.46. The company had revenue of $35.01 million for the quarter, compared to the consensus estimate of $22.52 million. Sarepta Therapeutics's revenue was up 350000.0% compared to the same quarter last year. During the same quarter last year, the business earned ($1.19) earnings per share. View Sarepta Therapeutics' Earnings History.

When will Sarepta Therapeutics make its next earnings announcement?

Sarepta Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, October, 25th 2017. View Earnings Estimates for Sarepta Therapeutics.

Where is Sarepta Therapeutics' stock going? Where will Sarepta Therapeutics' stock price be in 2017?

20 brokerages have issued 1-year price objectives for Sarepta Therapeutics' shares. Their predictions range from $27.00 to $101.00. On average, they expect Sarepta Therapeutics' share price to reach $63.70 in the next twelve months. View Analyst Ratings for Sarepta Therapeutics.

What are analysts saying about Sarepta Therapeutics stock?

Here are some recent quotes from research analysts about Sarepta Therapeutics stock:

  • 1. According to Zacks Investment Research, "Sarepta reported encouraging Q2 results, beating estimates on both counts. The company also raised its revenue guidance for 2017. Sarepta received a huge boost with the FDA approval of Exondys 51, the first DMD treatment to gain approval in the U.S. Also, a marketing application is under review in the EU, which, if approved, should augment sales. Moreover, the company’s collaboration agreements with Summit Pharmaceuticals and Catabasis as well as its own follow-on exon-skipping pipeline candidates represent the most comprehensive approach to treat DMD. Meanwhile, the settlement of the patent litigation with BioMarin removes a major overhang for Sarepta. However, Exondys 51’s commercial launch has been slower than expected due to slow patient starts and reimbursement hurdles. Nonetheless, Sarepta expects a pickup in patient starts and conversion rates as 2017 progresses. Meanwhile, the competitive RNA-based treatment market is a threat." (8/2/2017)
  • 2. Cowen and Company analysts commented, "SRPT reported 1Q17 results, including a slight Exondys 51 beat and raise; we see." (4/28/2017)
  • 3. Instinet analysts commented, "We are initiating coverage on Sarepta Therapeutics (SRPT) with a Buy rating and $84 target price. We recommend owning SRPT shares, expecting significant upside to materialize as Exondys 51 launch metrics begin to reflect an underestimated demand for the treatment and the ultimate patient numbers/market opportunity. We expect additional upside to be realized following EU approval of Exondys 51, which will help bolster perception of the drug's benefit and to define the EU opportunity, currently not reflected in shares." (3/1/2017)
  • 4. Needham & Company LLC analysts commented, "As previously reported, Sarepta earned $5.4M in 4Q16 Exondys revenue. The company gave 1Q and FY17 guidance for Exondys sales of $13-15M and >$80M, respectively. While the 1Q guidance number is relatively in line with our ($17M) and the Street's estimates, the low end of FY17 guidance is significantly below expectations and implies no acceleration in new patient starts through the back part of 2017. This sales guidance contrasts with management's qualitative commentary about accelerating conversion rates and we believe is explained by conservatism in an uncertain and dynamic reimbursement environment. We continue to expect that the majority of the 1,400+ eligible DMD boys in the US will ultimately be on therapy by implying a ~$400M Exondys US sales run rate." (3/1/2017)
  • 5. Royal Bank Of Canada analysts commented, "Sarepta provided sales guidance for EXONDYS 51 on tonight's call, which clearly disappointed investors (SRPT -15%AH). We didn't hear anything on the call to justify this level of selling: while FY17 guidance appears soft to us (>$80M) and doesn't exude confidence, guidance for 1Q17 ($13-$15 vs. $5.4M in 4Q16) and management's language about conversion rate acceleration, makes us view the >$80M guidance as beatable." (3/1/2017)

Who are some of Sarepta Therapeutics' key competitors?

Who are Sarepta Therapeutics' key executives?

Sarepta Therapeutics' management team includes the folowing people:

  • Douglas S. Ingram, President, Chief Executive Officer
  • Sandesh Mahatme, Executive Vice President, Chief Financial Officer and Chief Business Officer
  • David Tyronne Howton Jr., Senior Vice President, General Counsel, Corporate Secretary
  • Alexander Cumbo, Senior Vice President, Global Commercial Development
  • Shamim Ruff, Senior Vice President - Regulatory Affairs and Quality
  • Catherine Stehman-Breen M.D., Senior Vice President, Chief Medical Officer
  • Richard J. Barry, Independent Director
  • M. Kathleen Behrens Ph.D., Independent Director
  • Claude Nicaise M.D., Independent Director
  • Hans Wigzell M.D., Ph.D., Independent Director

Who owns Sarepta Therapeutics stock?

Sarepta Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (9.50%), Vanguard Group Inc. (7.75%), State Street Corp (4.92%), HealthCor Management L.P. (3.16%), FMR LLC (1.98%) and Emerald Advisers Inc. PA (1.59%). Company insiders that own Sarepta Therapeutics stock include Alexander Cumbo, David T Howton, Douglas S Ingram, Edward M Md Kaye, Jayant Aphale, M Kathleen Behrens, Sandesh Mahatme and Shamim Ruff. View Institutional Ownership Trends for Sarepta Therapeutics.

Who sold Sarepta Therapeutics stock? Who is selling Sarepta Therapeutics stock?

Sarepta Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Balyasny Asset Management LLC, Sphera Funds Management LTD., BlackRock Inc., Samlyn Capital LLC, Tudor Investment Corp ET AL, Teachers Advisors LLC, FMR LLC and TIAA CREF Investment Management LLC. Company insiders that have sold Sarepta Therapeutics stock in the last year include Alexander Cumbo, David T Howton, Edward M Md Kaye, Sandesh Mahatme and Shamim Ruff. View Insider Buying and Selling for Sarepta Therapeutics.

Who bought Sarepta Therapeutics stock? Who is buying Sarepta Therapeutics stock?

Sarepta Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Voya Investment Management LLC, HealthCor Management L.P., Eagle Asset Management Inc., Vanguard Group Inc., Quantitative Investment Management LLC, JPMorgan Chase & Co., Osterweis Capital Management Inc. and Emerald Mutual Fund Advisers Trust. Company insiders that have bought Sarepta Therapeutics stock in the last two years include Douglas S Ingram and M Kathleen Behrens. View Insider Buying and Selling for Sarepta Therapeutics.

How do I buy Sarepta Therapeutics stock?

Shares of Sarepta Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sarepta Therapeutics' stock price today?

One share of Sarepta Therapeutics stock can currently be purchased for approximately $46.73.

MarketBeat Community Rating for Sarepta Therapeutics (NASDAQ SRPT)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  792 (Vote Outperform)
Underperform Votes:  511 (Vote Underperform)
Total Votes:  1,303
MarketBeat's community ratings are surveys of what our community members think about Sarepta Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Sarepta Therapeutics (NASDAQ:SRPT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Hold Ratings, 15 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $63.70 (36.32% upside)

Analysts' Ratings History for Sarepta Therapeutics (NASDAQ:SRPT)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/15/2017Royal Bank Of CanadaInitiated CoveragePositiveLowView Rating Details
9/14/2017Cowen and CompanyReiterated RatingOutperform$69.00MediumView Rating Details
9/7/2017SunTrust Banks, Inc.Reiterated RatingBuy$56.00HighView Rating Details
9/7/2017William BlairReiterated RatingOutperformHighView Rating Details
9/7/2017Piper Jaffray CompaniesReiterated RatingOverweight$50.00 -> $55.00HighView Rating Details
9/7/2017Oppenheimer Holdings, Inc.Reiterated RatingBuy$76.00LowView Rating Details
9/7/2017Credit Suisse GroupBoost Price TargetOutperform$5.65 -> $81.00HighView Rating Details
9/6/2017Barclays PLCInitiated CoverageEqual Weight$46.00MediumView Rating Details
9/6/2017Needham & Company LLCReiterated RatingBuy$75.00LowView Rating Details
9/6/2017Robert W. BairdReiterated RatingOutperform$101.00LowView Rating Details
9/5/2017NomuraReiterated RatingBuy$84.00LowView Rating Details
7/24/2017Janney Montgomery ScottBoost Price TargetBuy -> Fair Value$65.00 -> $73.00HighView Rating Details
7/20/2017Morgan StanleyReiterated RatingEqual Weight$31.00 -> $33.00HighView Rating Details
7/18/2017Leerink SwannReiterated RatingBuy$52.00 -> $60.00LowView Rating Details
4/6/2017Jefferies Group LLCReiterated RatingHold$27.00MediumView Rating Details
3/11/2017J P Morgan Chase & CoSet Price TargetBuy$42.00HighView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$84.00N/AView Rating Details
3/1/2017JMP SecuritiesLower Price Target$48.00N/AView Rating Details
12/20/2016Goldman Sachs Group, Inc. (The)Initiated CoverageNeutral$40.00N/AView Rating Details
10/27/2016WedbushReiterated RatingOutperform$72.00N/AView Rating Details
9/20/2016WBB SecuritiesReiterated RatingStrong-Buy$40.00 -> $60.00N/AView Rating Details
5/5/2016Ladenburg Thalmann Financial ServicesDowngradeMarket Perform -> Underperform$13.00 -> $5.00N/AView Rating Details
11/8/2015Roth CapitalReiterated RatingBuy$50.00N/AView Rating Details
10/23/2015Bank of America CorporationInitiated CoverageBuy$49.00N/AView Rating Details
(Data available from 9/21/2015 forward)


Earnings History for Sarepta Therapeutics (NASDAQ:SRPT)
Earnings by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)
Earnings History by Quarter for Sarepta Therapeutics (NASDAQ SRPT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/25/2017($0.91)N/AView Earnings Details
7/19/2017Q2 2017($0.92)($0.46)$22.52 million$35.01 millionViewN/AView Earnings Details
4/27/2017Q1 2017($0.85)($0.73)$13.80 million$16.34 millionViewN/AView Earnings Details
2/28/2017Q416($1.33)($0.71)$4.86 million$5.42 millionViewListenView Earnings Details
10/27/2016Q316($1.32)($0.95)$1.06 millionViewListenView Earnings Details
7/19/2016Q2($1.19)($1.35)$1.10 millionViewN/AView Earnings Details
5/5/2016Q1($1.30)($1.15)$0.18 millionViewN/AView Earnings Details
2/24/2016Q4($1.18)($1.30)$1.25 millionViewN/AView Earnings Details
11/5/2015Q315($1.19)($1.25)ViewListenView Earnings Details
8/6/2015Q215($1.21)($1.01)$0.31 million$0.01 millionViewListenView Earnings Details
5/7/2015Q115($1.00)($1.49)$0.78 millionViewListenView Earnings Details
2/26/2015Q414($0.82)($0.94)$1.56 million$0.30 millionViewListenView Earnings Details
11/6/2014Q314($0.96)($0.70)$3.07 million$1.10 millionViewListenView Earnings Details
8/7/2014Q214($0.76)($0.85)$4.30 million$2.58 millionViewListenView Earnings Details
5/8/2014Q114($0.80)($0.75)$3.45 million$6.09 millionViewListenView Earnings Details
2/27/2014Q413($0.69)($0.77)$4.53 million$2.60 millionViewListenView Earnings Details
11/12/2013Q313($0.65)($0.63)$4.57 million$4.20 millionViewListenView Earnings Details
8/8/2013Q2 2013($0.67)($0.46)$5.08 million$3.00 millionViewListenView Earnings Details
5/9/2013Q1 2013($0.62)($0.41)$5.85 million$4.50 millionViewListenView Earnings Details
3/7/2013Q4 2012($0.26)($2.36)$6.71 million$7.30 millionViewListenView Earnings Details
11/7/2012($0.27)($2.17)$10.06 million$7.57 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Sarepta Therapeutics (NASDAQ:SRPT)
2017 EPS Consensus Estimate: ($2.69)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20176($1.15)$0.57($0.65)
Q2 20176($1.02)$1.22($0.26)
Q3 20176($1.17)($0.78)($0.94)
Q4 20176($1.02)($0.56)($0.84)
(Data provided by Zacks Investment Research)


Dividend History for Sarepta Therapeutics (NASDAQ:SRPT)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Sarepta Therapeutics (NASDAQ:SRPT)
Insider Ownership Percentage: 9.60%
Institutional Ownership Percentage: 65.41%
Insider Trades by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)
Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)
Insider Trades by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/27/2017Douglas S IngramCEOBuy47,058$42.50$1,999,965.00View SEC Filing  
7/21/2017Shamim RuffSVPSell12,138$42.97$521,569.86View SEC Filing  
7/20/2017Alexander CumboSVPSell5,918$41.00$242,638.00View SEC Filing  
7/20/2017Edward M Md KayeDirectorSell10,000$41.00$410,000.00View SEC Filing  
7/20/2017Sandesh MahatmeCFOSell50,000$41.00$2,050,000.00View SEC Filing  
10/17/2016Sandesh MahatmeInsiderSell30,000$50.08$1,502,400.00View SEC Filing  
9/22/2016David T HowtonSVPSell7,000$60.00$420,000.00View SEC Filing  
9/22/2016Edward M Md KayeCEOSell40,179$60.00$2,410,740.00View SEC Filing  
9/19/2016David T HowtonSVPSell9,304$50.00$465,200.00View SEC Filing  
9/19/2016Edward M Md KayeCEOSell24,352$50.00$1,217,600.00View SEC Filing  
9/19/2016Jayant AphaleVPSell35,000$50.00$1,750,000.00View SEC Filing  
9/14/2016Edward M Md KayeCEOSell24,557$30.00$736,710.00View SEC Filing  
3/16/2016M Kathleen BehrensDirectorBuy10,000$14.54$145,400.00View SEC Filing  
3/14/2016M Kathleen BehrensDirectorBuy65,000$16.54$1,075,100.00View SEC Filing  
11/14/2013Anthony ChaseDirectorBuy10,000$13.95$139,500.00View SEC Filing  
9/16/2013M Kathleen BehrensDirectorBuy6,500$37.04$240,760.00View SEC Filing  
9/3/2013John HodgmanDirectorSell5,556$34.97$194,293.32View SEC Filing  
8/22/2013Anthony ChaseDirectorBuy3,500$32.68$114,380.00View SEC Filing  
8/20/2013Sandesh MahatmeCFOBuy5,000$31.10$155,500.00View SEC Filing  
6/14/2013Anthony R ChaseDirectorBuy10,000$38.50$385,000.00View SEC Filing  
9/7/2012M Kathleen BehrensDirectorBuy17,500$14.73$257,775.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Sarepta Therapeutics (NASDAQ:SRPT)
Latest Headlines for Sarepta Therapeutics (NASDAQ:SRPT)
DateHeadline logoSarepta Therapeutics, Inc. (SRPT) Earns Positive Rating from Analysts at Royal Bank Of Canada - September 15 at 11:12 PM logoSarepta Therapeutics, Inc. (SRPT) Expected to Announce Quarterly Sales of $37.78 Million - September 15 at 11:00 AM logoSarepta Therapeutics, Inc. (SRPT) Given "Outperform" Rating at Cowen and Company - September 14 at 6:38 PM logoSarepta Therapeutics' (SRPT) CEO Douglas Ingram Presents at Morgan Stanley Healthcare Broker Conference ... - Seeking Alpha - September 14 at 10:39 AM logoSarepta Therapeutics' (SRPT) CEO Doug Ingram on Baird 2017 Global Healthcare Conference - Transcript - Seeking Alpha - September 14 at 10:39 AM logoSarepta Therapeutics, Inc. (SRPT) Rating Reiterated by Needham & Company LLC - September 10 at 5:52 PM logoSarepta Therapeutics, Inc. (SRPT) Rating Reiterated by Robert W. Baird - September 10 at 5:52 PM logoSarepta Therapeutics, Inc. (SRPT) Now Covered by Barclays PLC - September 10 at 5:16 PM logoSarepta Therapeutics, Inc. (SRPT) Price Target Raised to $81.00 at Credit Suisse Group - September 10 at 9:54 AM logoSarepta Therapeutics: Golodirsen Data Is A Gamechanger - Seeking Alpha - September 10 at 8:11 AM logoSarepta Therapeutics (SRPT) Phase 1/2 Study of Golodirsen in DMD Hits Statistical Significance on all Primary and Secondary Endpoints - September 8 at 8:41 AM logoQ3 2017 EPS Estimates for Sarepta Therapeutics, Inc. Raised by Analyst (SRPT) - September 8 at 5:40 AM logoSarepta Therapeutics, Inc. (SRPT) Stock Rating Reaffirmed by Piper Jaffray Companies - September 7 at 5:16 PM logoSarepta Therapeutics, Inc. (SRPT) Stock Rating Reaffirmed by SunTrust Banks, Inc. - September 7 at 5:16 PM logoWilliam Blair Reiterates Outperform Rating for Sarepta Therapeutics, Inc. (SRPT) - September 7 at 5:16 PM logoSarepta Therapeutics' (SRPT) Buy Rating Reiterated at Oppenheimer Holdings, Inc. - September 7 at 3:26 PM logoFY2019 EPS Estimates for Sarepta Therapeutics, Inc. Increased by Leerink Swann (SRPT) - September 7 at 3:02 PM logoSarepta shares surge 14% on positive early/mid-stage clinical trial results in DMD - MarketWatch - September 7 at 9:20 AM logoShares of drugmaker that targets gene mutations soar after positive study results - September 6 at 9:25 AM logoSarepta Therapeutics (SRPT) Phase 1/2 Study of Golodirsen in ... - - September 6 at 8:35 AM logoSarepta Therapeutics, Inc. (Nasdaq: SRPT) to Ring The Nasdaq Stock Market Closing Bell - GlobeNewswire (press release) - September 6 at 8:35 AM logoNomura Reiterates "Buy" Rating for Sarepta Therapeutics, Inc. (SRPT) - September 5 at 4:44 PM logoSarepta Therapeutics, Inc. (SRPT) Receives Average Rating of "Buy" from Analysts - September 5 at 2:40 PM logoSarepta Therapeutics, Inc. (Nasdaq: SRPT) to Ring The Nasdaq Stock Market Closing Bell - September 5 at 10:42 AM logo$37.78 Million in Sales Expected for Sarepta Therapeutics, Inc. (SRPT) This Quarter - August 27 at 3:34 AM logoZacks: Analysts Anticipate Sarepta Therapeutics, Inc. (SRPT) Will Announce Earnings of -$0.89 Per Share - August 25 at 4:28 PM logoStock Traders Buy High Volume of Call Options on Sarepta Therapeutics (SRPT) - August 25 at 2:50 AM logoWhy Is Sarepta (SRPT) Down 9.9% Since the Last Earnings Report? - August 24 at 6:22 PM logoSarepta Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : SRPT-US : August 22, 2017 - August 24 at 6:22 PM logoSarepta Therapeutics to Present at Three Upcoming Investor Conferences - GlobeNewswire (press release) - August 24 at 1:19 PM logoSarepta Therapeutics: Backing A Cure For Duchenne Muscular Dystrophy - Seeking Alpha - August 23 at 12:00 PM logoWhy Is Sarepta (SRPT) Down 9.9% Since the Last Earnings Report? - Nasdaq - August 23 at 12:00 PM logoSarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Recommendation of "Buy" by Analysts - August 11 at 3:08 PM logoSarepta Therapeutics, Inc. (SRPT) Expected to Post Quarterly Sales of $37.59 Million - August 9 at 7:24 AM logoSarepta Therapeutics, Inc. (NASDAQ:SRPT) Expected to Post Earnings of -$0.89 Per Share - August 7 at 8:54 AM logoSarepta Therapeutics, Inc. (NASDAQ:SRPT) Lowered to Hold at BidaskClub - August 4 at 8:06 PM logoWhy Sarepta Therapeutics Stock Gained 10.7% in July - August 4 at 7:43 AM logoSarepta Therapeutics, Inc. (SRPT) Upgraded to "Hold" by Zacks Investment Research - August 2 at 1:08 PM logoToday's Research Reports on Trending Tickers: Sarepta Therapeutics Inc. and GW Pharmaceuticals Plc - August 1 at 4:13 PM logoSarepta Therapeutics Inc (SRPT) President & CEO Douglas S Ingram Bought $2 million of Shares - July 29 at 7:29 AM logoInsider Buying: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) CEO Acquires 47,058 Shares of Stock - July 28 at 10:39 AM logoSarepta Therapeutics (SRPT) Partner Genethon Publishes New ... - - July 28 at 8:15 AM logoSarepta Therapeutics' (NASDAQ:SRPT) "Outperform" Rating Reaffirmed at William Blair - July 27 at 5:14 PM logoSarepta Therapeutics (SRPT) Plans $250M Public Offering of Common Stock; CEO to Buy $2M in Stock - July 25 at 6:55 AM logoSarepta Therapeutics, Inc. (NASDAQ:SRPT) PT Raised to $73.00 at Janney Montgomery Scott - July 24 at 11:01 AM logoShamim Ruff Sells 12,138 Shares of Sarepta Therapeutics, Inc. (SRPT) Stock - July 24 at 8:48 AM logoQ3 2017 EPS Estimates for Sarepta Therapeutics, Inc. (SRPT) Reduced by Oppenheimer Holdings - July 24 at 7:22 AM logoLeerink Swann Weighs in on Sarepta Therapeutics, Inc.'s Q3 2017 Earnings (NASDAQ:SRPT) - July 24 at 7:21 AM logoQ3 2017 EPS Estimates for Sarepta Therapeutics, Inc. Decreased by SunTrust Banks (NASDAQ:SRPT) - July 24 at 7:21 AM logoSarepta Therapeutics, Inc. to Post Q3 2017 Earnings of ($0.92) Per Share, William Blair Forecasts (SRPT) - July 24 at 7:21 AM



Sarepta Therapeutics (SRPT) Chart for Thursday, September, 21, 2017

This page was last updated on 9/21/2017 by Staff